Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwideIf approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity1These positive results follow the r ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca's SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.1 The safety profile observed in the interim analysis was consistent with the known clinical profile of SAP. ...